ES2666562T3 - Brazos autorreactivos y profármacos que los comprenden - Google Patents

Brazos autorreactivos y profármacos que los comprenden Download PDF

Info

Publication number
ES2666562T3
ES2666562T3 ES11724800.5T ES11724800T ES2666562T3 ES 2666562 T3 ES2666562 T3 ES 2666562T3 ES 11724800 T ES11724800 T ES 11724800T ES 2666562 T3 ES2666562 T3 ES 2666562T3
Authority
ES
Spain
Prior art keywords
compound
group
represent
chosen
general formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11724800.5T
Other languages
English (en)
Spanish (es)
Inventor
Sébastien PAPOT
Mickaël THOMAS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Original Assignee
Centre National de la Recherche Scientifique CNRS
Universite de Poitiers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Centre National de la Recherche Scientifique CNRS, Universite de Poitiers filed Critical Centre National de la Recherche Scientifique CNRS
Application granted granted Critical
Publication of ES2666562T3 publication Critical patent/ES2666562T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A61K47/551—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug one of the codrug's components being a vitamin, e.g. niacinamide, vitamin B3, cobalamin, vitamin B12, folate, vitamin A or retinoic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C205/00—Compounds containing nitro groups bound to a carbon skeleton
    • C07C205/13—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups
    • C07C205/20—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings
    • C07C205/21—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring
    • C07C205/22—Compounds containing nitro groups bound to a carbon skeleton the carbon skeleton being further substituted by hydroxy groups having nitro groups and hydroxy groups bound to carbon atoms of six-membered aromatic rings having nitro groups and hydroxy groups bound to carbon atoms of the same non-condensed six-membered aromatic ring having one nitro groups bound to the ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D475/00—Heterocyclic compounds containing pteridine ring systems
    • C07D475/02—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4
    • C07D475/04—Heterocyclic compounds containing pteridine ring systems with an oxygen atom directly attached in position 4 with a nitrogen atom directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/203—Monocyclic carbocyclic rings other than cyclohexane rings; Bicyclic carbocyclic ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/20—Carbocyclic rings
    • C07H15/24—Condensed ring systems having three or more rings
    • C07H15/252—Naphthacene radicals, e.g. daunomycins, adriamycins

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Saccharide Compounds (AREA)
  • Medicinal Preparation (AREA)
ES11724800.5T 2010-05-20 2011-05-18 Brazos autorreactivos y profármacos que los comprenden Active ES2666562T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
FR1053921 2010-05-20
FR1053921A FR2960153B1 (fr) 2010-05-20 2010-05-20 Nouveaux bras autoreactifs et prodrogues les comprenant
PCT/IB2011/052184 WO2011145068A1 (fr) 2010-05-20 2011-05-18 Nouveaux bras autoréactifs et prodrogues les comprenant

Publications (1)

Publication Number Publication Date
ES2666562T3 true ES2666562T3 (es) 2018-05-07

Family

ID=43063203

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11724800.5T Active ES2666562T3 (es) 2010-05-20 2011-05-18 Brazos autorreactivos y profármacos que los comprenden

Country Status (7)

Country Link
US (1) US9000135B2 (enExample)
EP (1) EP2571528B1 (enExample)
JP (1) JP6223824B2 (enExample)
CA (1) CA2799773C (enExample)
ES (1) ES2666562T3 (enExample)
FR (1) FR2960153B1 (enExample)
WO (1) WO2011145068A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3017298B1 (fr) 2014-02-07 2016-03-04 Centre Nat Rech Scient Conjugues et pro-drogues pour le traitement du cancer et de maladies inflammatoires
KR101628872B1 (ko) 2014-05-28 2016-06-09 주식회사 레고켐 바이오사이언스 자가-희생 기를 포함하는 화합물
EP3160513B1 (en) 2014-06-30 2020-02-12 Glykos Finland Oy Saccharide derivative of a toxic payload and antibody conjugates thereof
AU2016230008B2 (en) * 2015-03-06 2020-08-27 Colorado State University Research Foundation Synthesis and utility of new capgroup largazole analogs
KR102368068B1 (ko) 2015-08-24 2022-02-25 삼성전자주식회사 반도체 소자 제조용 조성물 및 이를 이용하는 반도체 소자의 제조 방법
LT3380124T (lt) 2015-11-25 2024-06-25 Ligachem Biosciences Inc. Konjugatai, apimantys savaime skaidančias grupes, ir su jais susiję būdai
US11167040B2 (en) 2015-11-25 2021-11-09 Legochem Biosciences, Inc. Conjugates comprising peptide groups and methods related thereto
CN107847605B (zh) * 2015-11-25 2021-12-24 乐高化学生物科学股份有限公司 包含分支接头的抗体-药物缀合物及其相关方法
KR102085798B1 (ko) 2016-12-28 2020-03-06 주식회사 인투셀 베타-갈락토사이드가 도입된 자가-희생 기를 포함하는 화합물
KR101938800B1 (ko) 2017-03-29 2019-04-10 주식회사 레고켐 바이오사이언스 피롤로벤조디아제핀 이량체 전구체 및 이의 리간드-링커 접합체 화합물
EP3624854B1 (en) 2017-05-16 2026-04-15 Université de Strasbourg Protein-drug conjugates and their use in the treatment of cancers
CN112004556A (zh) * 2018-04-03 2020-11-27 辛迪维亚公司 细胞毒性药物的结合物和所述结合物的前体药物形式
IL278480B1 (en) 2018-05-09 2026-04-01 Ligachem Biosciences Inc Compositions and methods related to anti-CD19 antibody drug conjugates
KR102258299B1 (ko) * 2019-03-21 2021-05-28 고려대학교 산학협력단 대장암 선택적 항암 치료진단제
KR20210028544A (ko) 2019-09-04 2021-03-12 주식회사 레고켐 바이오사이언스 인간 ror1에 대한 항체를 포함하는 항체 약물 접합체 및 이의 용도
US12227522B2 (en) 2020-12-21 2025-02-18 Colorado State University Research Foundation Synthesis of structural analogs of largazole and associated compounds
EP4274619A4 (en) * 2021-01-08 2025-09-24 Lycia Therapeutics Inc BIFUNCTIONAL FOLATE RECEPTOR-BINDING COMPOUNDS
BR112023019495A2 (pt) 2021-03-30 2023-11-07 Centre Nat Rech Scient Ligante de autorreação induzida por enzima tendo propriedades fisicoquímicas e farmacológicas melhoradas
WO2022272307A1 (en) * 2021-06-24 2022-12-29 Lycia Therapeutics, Inc. Bifunctional folate receptor binding compounds
JP2024524614A (ja) 2021-07-14 2024-07-05 ライシア セラピューティクス， インコーポレイテッド Ａｓｇｐｒ細胞表面受容体結合化合物及びコンジュゲート
FR3126982B1 (fr) 2021-09-14 2023-09-15 Centre Nat Rech Scient Vecteurs ciblant la beta-d-n-acetylglucosaminidase
EP4713369A1 (en) * 2023-05-17 2026-03-25 OncoC4, Inc. Ph-sensitive anti-ctla-4 antibodies and uses thereof
EP4534101A1 (en) 2023-10-02 2025-04-09 Eli Lilly and Company Antibody drug conjugate (adc) targeting nectin 4 and comprising an exatecan payload

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1981001145A1 (en) 1979-10-18 1981-04-30 Univ Illinois Hydrolytic enzyme-activatible pro-drugs
US4379166A (en) * 1981-08-03 1983-04-05 Schering Corporation Arylmethoxy-, arylmethylthio-, heteroarylmethoxy-, and heteroarylmethylthio-alkylaminoalcohols
PT97858A (pt) * 1990-06-05 1992-03-31 Glaxo Group Ltd Metodo para a preparacao de um composto dicloroanilina tendo um substituinte contendo um grupo piridinilo
FR2676058B1 (fr) * 1991-04-30 1994-02-25 Hoechst Lab Prodrogues glycosylees, leur procede de preparation et leur utilisation dans le traitement des cancers.
EP0647450A1 (en) * 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
ATE380559T1 (de) * 1994-08-19 2007-12-15 Wallone Region Konjugate enthaltend ein antitumorales mittel und deren verwendung
FR2852606A1 (fr) * 2003-03-18 2004-09-24 Inst Nat Sante Rech Med Moyens pour inhiber simultanement l'expression de plusieurs genes impliques dans une pathologie
WO2005115105A2 (en) * 2004-05-10 2005-12-08 Northwestern University Self-immolative magnetic resonance imaging contrast agents sensitive to beta-glucuronidase
EP2098533A1 (en) 2008-03-07 2009-09-09 Pharmachemie B.V. Esters of glucuronide prodrugs of anthracyclines and method of preparation and use in tumor-selective chemotherapy

Also Published As

Publication number Publication date
FR2960153B1 (fr) 2012-08-17
CA2799773A1 (fr) 2011-11-24
JP2013532132A (ja) 2013-08-15
EP2571528A1 (fr) 2013-03-27
WO2011145068A1 (fr) 2011-11-24
US9000135B2 (en) 2015-04-07
CA2799773C (fr) 2019-10-22
FR2960153A1 (fr) 2011-11-25
US20130144045A1 (en) 2013-06-06
EP2571528B1 (fr) 2018-01-31
JP6223824B2 (ja) 2017-11-01

Similar Documents

Publication Publication Date Title
JP6223824B2 (ja) 新規な自己反応性アーム及び同物を含むプロドラッグ
US10905762B2 (en) Targeted nanoparticle conjugates
TWI808931B (zh) 包含分支連接子之抗體-藥物結合物及與其相關之方法
ES2735348T3 (es) Conjugados de fármaco de molécula pequeña
JP2020507584A (ja) 癌選択的標識および標的化のためのトリガー活性化可能な糖コンジュゲート
TWI787153B (zh) 關於抗-egfr抗體藥物共軛物之組合物及方法
KR20200083605A (ko) 프로그램가능한 중합체성 약물
WO2017062800A1 (en) Trigger-activatable metabolic sugar precursors for cancer-selective labeling and targeting
CN102060991A (zh) 7-乙基-10-羟基喜树碱的两亲性药物前体及其制备方法
Rades et al. Reductively cleavable polymer-drug conjugates based on dendritic polyglycerol sulfate and monomethyl auristatin E as anticancer drugs
Shi et al. Folate-dactolisib conjugates for targeting tubular cells in polycystic kidneys
Assali et al. Combretastatin A4-camptothecin micelles as combination therapy for effective anticancer activity
Patil et al. Synthesis, characterization and in vitro evaluation of novel vitamin D3 nanoparticles as a versatile platform for drug delivery in cancer therapy
Liu et al. Design, synthesis and biological activity evaluation of a series of bardoxolone methyl prodrugs
WO2022085523A1 (ja) 複合体およびその利用
JP5649647B2 (ja) 酸に不安定なトリガーユニット
CN102492009A (zh) 喜树碱20位胆酸衍生物及其制备方法
Shao et al. Design of a prodrug photocage for cancer cells detection and anticancer drug release
KR20230149767A (ko) Ddx5 단백질에 결합하는 캄토테신 유도체 및 이의 프로드럭
CN109761915B (zh) 靶向mct1转运体的5-氟尿嘧啶成酯前药
WO2023078230A1 (zh) 一种包含sn38的抗体药物偶联物中间体及其制备方法
CN107868141A (zh) 一种β环糊精衍生物的合成方法
CN112979491B (zh) 一种包含过氧化氢/组织蛋白酶l响应性保护基的化合物及其应用
JP7620569B2 (ja) がん治療のための新規治療用ベクター及びプロドラッグ
US20250161506A1 (en) Antibody Drug Conjugate Based on Metal N-Heterocyclic Carbene Complex, a Method of Preparing the Same and the Use of the Same in Anticancer Treatment